CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Navigating Acute and Late-Onset Toxicities After Chimeric Antigen Receptor T-Cell Therapy: A Patient-Centered Nursing Approach.
Navigating Acute and Late-Onset Toxicities After Chimeric Antigen Receptor T-Cell Therapy: A Patient-Centered Nursing Approach.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
接受CAR-T 细胞疗法等先进疗法的癌症患者,会出现复杂的治疗相关毒性反应,需要及时识别和管理。护士通过教育、监测和干预来优化治疗结果,并为患者提供高质量的生存期照护支持。
本文重点介绍了管理治疗相关并发症的循证干预措施,并概述了在CAR-T 细胞治疗全程中支持安全、高质量护理的策略。
作者通过检索PubMed、CINAHL及关键肿瘤护理指南进行文献综述,检视相关研究、指南及专家共识声明,以综合免疫治疗并发症护理评估与管理的最佳实践。
临床医生通过早期识别毒性、标准化评估方案和多学科协作来确保安全有效的医疗照护。循证干预以及心理支持有助于改善患者结局。持续教育和专业发展仍然至关重要。
Patients with cancer undergoing advanced therapies, such as chimeric antigen receptor (CAR) T-cell therapy, experience complex treatment-related toxicities that require timely recognition and management. Nurses educate, monitor, and intervene to optimize outcomes and support quality survivorship care for patients.
This article highlights evidence-based interventions for managing treatment-related complications and outlines strategies to support safe, high-quality care throughout CAR T-cell treatment.
The author conducted a literature review using PubMed , CINAHL , and key oncology nursing guidelines to examine relevant studies, guidance, and expert consensus statements to synthesize best practices for nursing assessment and management of immune-based therapy complications.
Clinicians ensure safe and effective care through early toxicity recognition, standardized assessment protocols, and multidisciplinary coordination. Evidence-based interventions, as well as psychological support, contribute to improved patient outcomes. Ongoing education and professional development remain essential.
MEMBER ACCOUNT
登录成功会直接打开下一页。